#USA #San Diego #Viking Therapeutics #VK2735 #ObesityWeek

Viking Therapeutics Showcases VK2735 Results at ObesityWeek® 2025

Viking Therapeutics, a clinical-stage biopharmaceutical firm, recently highlighted significant findings from its VK2735 obesity program at ObesityWeek 2025. This annual meeting, organized by The Obesity Society, serves as a platform for advancements in the understanding and treatment of obesity and its comorbidities.

VK2735 is an innovative dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The drug aims to address various metabolic disorders, including obesity. The company is currently testing both subcutaneous and oral forms of VK2735 in a range of clinical trials.

During this year’s ObesityWeek, results from the Phase 2 VENTURE clinical trial were presented, showcasing VK2735’s ability to improve cardiometabolic parameters over a 13-week treatment period. Notably, the exploratory analysis connected VK2735 treatment to a marked decrease in the prevalence of prediabetes and metabolic syndrome among participants.

Key Findings from the Study

The analysis found that 78% of patients who were classified as prediabetic at the beginning of the trial achieved normal glycemic status by week 13 when receiving VK2735. In contrast, only 29% of those in the placebo group experienced similar improvements, showcasing the significant efficacy of VK2735 (p=0.0008). This data indicates VK2735's potential to not only halt but also possibly reverse the progression from prediabetes to diabetes.

Moreover, the results showed a substantial 68% of VK2735-treated individuals meeting the criteria for metabolic syndrome at baseline experienced a return to normal levels by week 13, compared to 38% in the placebo group (p=0.02). Clearly, these outcomes highlight VK2735's capacity to enhance cardiometabolic health significantly.

Clinical Data Highlights

The impact of VK2735 on the patients' health was substantial:

• - Prediabetes Transition: Among VK2735 recipients, 78% moved from a prediabetic state to normal glycemic status compared to 29% in the placebo group.
• - Metabolic Syndrome Reversal: 68% of those initially classified with metabolic syndrome saw improvement with VK2735 treatment, versus 38% for placebo patients.

Dr. Brian Lian, CEO of Viking, emphasized the importance of these findings. He stated, "The results from our analyses add a crucial layer of validation to the impressive overall data reported from the VENTURE trial. The rapid improvement in glycemic status hints at VK2735’s potential to lower the risk of transitioning from prediabetes to diabetes while also potentially aiding individuals with metabolic syndrome to reverse their conditions, thus reducing associated cardiovascular risks."

Future Directions at ObesityWeek

Besides discussing VK2735's outcomes, Viking also shed light on the ongoing Phase 3 VANQUISH-1 study, which aims to evaluate VK2735’s efficacy in patients suffering from obesity and related comorbidities. This study will prioritize body weight changes as a primary endpoint while also assessing improvements in physical function and mental health.

Initial results from the VENTURE study indicate that VK2735 led to statistically significant weight loss over the 13-week span, averaging reductions of up to 14.7% from baseline. Moreover, a remarkable 88% of patients on VK2735 recorded at least a 10% weight loss, in contrast to a mere 4% of those on placebo.

Concluding Remarks

With encouraging safety and tolerability profiles observed during the trial, VK2735 emerges as a potent candidate in the fight against obesity and related metabolic disorders. Viking’s focus on innovative therapeutics for metabolic challenges continues to suggest that VK2735 could enhance the quality of life for many patients struggling with these conditions.

To discover more about Viking Therapeutics and its groundbreaking work, visit www.vikingtherapeutics.com.